FDA Grants Accelerated Approval to AstraZeneca Kidney Disease Treatment
The FDA approved AstraZeneca’s treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can lead to renal failure.
AstraZeneca (LSE:AZN) said on Wednesday that the US Food and Drug Administration granted accelerated approval to its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can lead to renal failure.